Niagen Bioscience (NAGE) Insider Wendy Buys 31,746 Shares

On June 24, 2026, insider Yu Wing Tak Wendy bought 31,746 shares of Niagen Bioscience, Inc. (NAGE) at a price of $3.42 per share, which totals about $108,700. This purchase reflects growing insider confidence amid recent trading activity in the company.

Inside Yu Wing Tak Wendy's Trade

Wendy's trade adds to a series of insider purchases on the same day. Along with Wendy, insiders Hamed Shahbazi, Steven Rubin, Kristin Patrick, and Ann Cohen each purchased 31,746 shares. These transactions signal a collective move to reinforce their stakes in the company as they each bought shares at the same price.

Other Institutional Activity in Niagen Bioscience

Several other institutional investors have also adjusted their positions in Niagen Bioscience. Blackrock Inc. holds 4,184,659 shares after increasing its stake by 313,201 shares. SteelPeak Wealth, LLC now has 3,500,129 shares after adding 127,161 shares. However, Vanguard Capital Management LLC and Tieton Capital Management, LLC reduced their stakes slightly, ending with 2,147,018 and 2,008,470 shares, respectively.

Niagen Bioscience, Inc. Stock Up 14.4%

As of Saturday, the stock trades at $3.42, close to its 52-week low of $2.87. This price point is notable as it suggests the stock has been struggling, especially compared to its 52-week high of $10.52. Investors will be watching to see how further insider activity affects market perception.

Recent Earnings

In its last earnings report, Niagen Bioscience posted revenue of $129.1 million, showing a decline of 4.3% year-over-year. The company has an EPS of $0.19 and a net margin of 12.4%, indicating a solid profitability level despite the revenue drop. The next earnings date is set for November 3, 2026.

Insider Buying and Selling at Niagen Bioscience, Inc.

On June 24, 2026, insiders made notable purchases. Hamed Shahbazi, Steven Rubin, Kristin Patrick, and Ann Cohen each bought 31,746 shares. The average price for these trades was the same as the market price, indicating their shared commitment to the company’s future.

About Niagen Bioscience

Niagen Bioscience, Inc. focuses on developing products that promote healthy aging. The company operates through various segments, including consumer products and pharmaceuticals. Given the recent insider purchases, it appears that the leadership is showing faith in the company's direction.

Bottom Line

Investors should keep an eye on Niagen Bioscience as it approaches its next earnings date on November 3, 2026. The recent insider activity may signal confidence in the company as it navigates current market challenges. Remember, the insider transactions reflect past trades and may not represent current positions.